Bedrijfsoverzicht
Lyra Therapeutics, Inc. is a clinical-stage biotechnology enterprise dedicated to the research, development, and commercialization of anti-inflammatory therapeutic solutions specifically designed for patients suffering from chronic rhinosinusitis. The company operates within the broader Healthcare sector, functioning specifically in the Biotechnology industry, which typically involves high capital expenditure and extended research timelines before achieving commercial product approvals. As a small-cap entity, Lyra Therapeutics holds a market capitalization of $1.15M and employs a workforce of 27 individuals, while reporting trailing twelve-month revenue of $398,000. These financial metrics indicate that the company occupies a nascent position in the market, characterized by minimal revenue generation and a very small market valuation relative to established peers. The combination of a market cap under two million dollars and annual revenue below half a million dollars suggests the company is currently in an early-stage development phase where commercial sales have not yet scaled significantly to offset operational costs.
Financiële gezondheid
The company reported trailing twelve-month revenue of $398,000, yet it simultaneously recorded a net income of $-28,919,000 and an EBITDA of $-29,094,000, revealing a substantial disconnect between top-line revenue and bottom-line profitability. This significant gap between revenue and net income highlights a cost structure heavily weighted toward research and development expenses or other operational costs that far exceed the current scale of sales. Free cash flow stands at $-17,529,624, indicating that the company is burning cash at a rapid rate, which limits its financial flexibility and reliance on external capital raises to fund ongoing operations. When analyzing profitability margins, the gross margin is recorded at -152.8%, the operating margin at -98728.6%, and the profit margin at 0.0%, figures that collectively signal severe operational inefficiencies or extensive upfront costs relative to current sales volume. The balance sheet presents a complex picture with cash holdings of $15.89M contrasted against total debt obligations of $30.26M, while the debt-to-equity ratio is listed as N/A due to the company's capitalization structure. Despite the debt exceeding cash reserves, the current ratio of 1.71 suggests that the company maintains a level of short-term liquidity where current assets are more than sufficient to cover current liabilities. Return on Equity is calculated at -6595.0% and Return on Assets at -36.1%, metrics that reveal the company is currently destroying value for shareholders and utilizing assets in a manner that does not yet generate positive returns.
Waarderingsbeoordeling
Valuation multiples for Lyra Therapeutics reflect its unprofitable status, with a P/E Ratio (TTM) listed as N/A and a Forward P/E of -0.66, implying that the market is not pricing the stock based on current or near-term earnings but rather on potential future value or asset backing. The price-to-book ratio is stated as -0.25, which indicates a valuation significantly below the company's book value, often seen in distressed or pre-revenue biotech firms where market capitalization is negative relative to equity. Alternative valuation metrics provide further insight, with a price-to-sales ratio of 2.90 and an EV/EBITDA of -0.53, suggesting the market is willing to pay a premium relative to sales despite the negative earnings multiple, likely betting on the clinical potential of its anti-inflammatory therapies. Historical price action shows a 52-week high of $37.50 and a 52-week low of $0.31, placing the current stock price at a level that requires precise calculation relative to this volatile range to determine if it is trading near historical peaks or troughs. The stock exhibits a Beta of 0.30, indicating that the price volatility of LYRA is substantially lower than the broader market, suggesting the share price is less sensitive to general market movements compared to large-cap equities.
Growth & Income
Revenue growth year-over-year is recorded at -96.7%, while earnings growth is N/A, indicating that the company is experiencing a contraction in revenue and lacks a measurable earnings growth trajectory to evaluate. The divergence between negative revenue growth and the absence of positive earnings growth implies that the company is still in a phase where commercial expansion has stalled or regressed rather than scaled. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that all available resources are being reinvested into research, development, and operational scaling rather than distributed to shareholders. The overall growth and income profile of Lyra Therapeutics is characterized by significant revenue contraction and a complete absence of dividend income, reflecting the high-risk, high-reward nature of a clinical-stage biotechnology company that has not yet achieved commercial sustainability.